Shah Nimish P

CIK 000169808211 companiesNEW YORK, NY

SEC Profile

Transactions

Companies

Filings

CIK

0001698082

Recent Transactions

50 trades

Purchase
Apogee Therapeutics, Inc.$APGE
Pre-Funded Warrants (Right to Buy)
2025-10-10$41.00/sh+365,853→ 365,853 total
Award
Apogee Therapeutics, Inc.$APGE
Stock Option (Right to Buy)
2025-06-17+14,461→ 14,461 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2025-04-09$9.42/sh+25,000→ 5,303,985 total
Purchase
Oruka Therapeutics, Inc.$ORKA
Common Stock
2025-02-14$11.44/sh+88,794→ 4,148,428 total
Purchase
Oruka Therapeutics, Inc.$ORKA
Common Stock
2025-02-13$11.63/sh+14,950→ 4,059,634 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2025-02-13$9.33/sh+61,700→ 5,278,985 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2025-02-12$9.23/sh+100,000→ 5,217,285 total
Purchase
Oruka Therapeutics, Inc.$ORKA
Common Stock
2025-02-12$11.86/sh+8,971→ 4,044,684 total
Purchase
Oruka Therapeutics, Inc.$ORKA
Common Stock
2025-02-11$10.95/sh+9,593→ 4,035,713 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2025-02-11$9.18/sh+26,703→ 5,117,285 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2025-02-10$9.14/sh+4,137→ 5,090,582 total
Purchase
Oruka Therapeutics, Inc.$ORKA
Common Stock
2025-02-10$10.90/sh+574→ 4,026,120 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2025-02-07$9.29/sh+73,649→ 5,086,445 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2025-02-03$9.22/sh+14,562→ 5,012,796 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2025-01-31$8.89/sh+11,754→ 4,998,234 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2025-01-30$8.76/sh+43,707→ 4,986,480 total
Award
Apogee Therapeutics, Inc.$APGE
Stock Option (Right to Buy)
2024-06-05+10,370→ 10,370 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Pre-Funded Warrants (Right to Buy)
2024-02-20$15.25/sh+655,738→ 655,738 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-02-08$14.70/sh+29,747→ 4,824,731 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-02-07$14.56/sh+51,827→ 4,794,984 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-02-06$14.74/sh+4,474→ 4,743,157 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-30$14.47/sh+88,099→ 4,738,683 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-29$14.22/sh+80,600→ 4,650,584 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-26$12.98/sh+4,174→ 4,569,984 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-25$12.73/sh+7,030→ 4,565,810 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-24$12.44/sh+20,686→ 4,558,780 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-23$12.54/sh+10,897→ 4,538,094 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-22$12.55/sh+67,546→ 4,527,197 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-19$12.43/sh+25,000→ 4,459,651 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-18$12.51/sh+39,680→ 4,434,651 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-17$12.60/sh+78,925→ 4,394,971 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-16$12.73/sh+19,599→ 4,316,046 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-11$12.68/sh+6,647→ 4,296,447 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-10$12.67/sh+47,700→ 4,289,800 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-09$12.56/sh+20,816→ 4,242,100 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-08$12.44/sh+69,184→ 4,221,284 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-04$12.11/sh+41,764→ 4,152,100 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2024-01-03$12.20/sh+17,605→ 4,110,336 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2023-12-29$12.49/sh+6,013→ 4,092,731 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2023-12-28$12.50/sh+471,490→ 4,086,718 total
Purchase
KalVista Pharmaceuticals, Inc.$KALV
Common Stock
2023-12-27$11.97/sh+41,514→ 3,615,228 total
Award
Apogee Therapeutics, Inc.$APGE
Stock Option (Right to Buy)
2023-07-13+47,758→ 47,758 total
Purchase
Apogee Therapeutics, Inc.$APGE
Common Stock
2023-07-13$17.00/sh+1,750,000→ 1,750,000 total
Sale
Tricida, Inc.
Common Stock
2022-10-26$0.46/sh−2,367,174→ 3,751,406 total
Sale
Tricida, Inc.
Common Stock
2022-10-25$0.57/sh−1,970,418→ 6,118,580 total
Sale
Tricida, Inc.
Common Stock
2022-10-24$0.61/sh−2,113,948→ 8,088,998 total
Purchase
Tricida, Inc.
Common Stock
2022-10-19$10.29/sh+241,366→ 10,132,846 total
Purchase
Tricida, Inc.
Common Stock
2022-10-19$11.25/sh+70,100→ 10,202,946 total
Purchase
Tricida, Inc.
Common Stock
2022-10-18$11.98/sh+40,400→ 9,891,480 total
Purchase
Tricida, Inc.
Common Stock
2022-10-17$11.67/sh+170,292→ 9,851,080 total

Companies

Recent Filings

Address

C/O VENROCK 7 BRYANT PARK, 23RD FLOOR

NEW YORK, NY, 10018

View on SEC.gov